BioCryst Pharmaceuticals (BCRX)
(Delayed Data from NSDQ)
$7.52 USD
-0.33 (-4.20%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $7.51 -0.01 (-0.13%) 7:58 PM ET
1-Strong Buy of 5 1
F Value C Growth F Momentum F VGM
Brokerage Reports
BioCryst Pharmaceuticals, Inc. [BCRX]
Reports for Purchase
Showing records 21 - 40 ( 176 total )
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Spotlight On BXC9930, Early Success for Factor D Inhibition; PT to $19
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Orladeyo Three-Pronged Commercial Strategy With BCX9930 in its Wake
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Orladeyo Approval Paves Way for Oral HAE Therapy; PT to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Orladeyo Strategy In-Place Awaiting Approvals; With Broad Early Pipeline In Tow
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Focus Remains on Oraldeyo Approval in 4Q20, With Underappreciated COVID-19 Play; Reit Buy and $13 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
With Potential Berotralstat Approval on 2020 Horizon
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
BCX9930 Complement Inhibitor Program Can Provide Traction for Deeper Developmental Pipeline
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Positive Phase 1 BCX9930 Data Paves Way for PoC in PNH Patients; Reit Buy and $13 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
NDA Is Underway While We Reframe the Commercial Potential; Reit Buy and $13 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Our Thoughts and KOL Feedback Following the ApeX-2 Topline; Reit Buy and $13 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
KOL Feedback Previews the Upcoming ApeX-2 Data in HAE; Reit Buy and $13 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Underappreciated Discovery Platform Continues to Prove Fruitful While HAE Timelines Remain In-tact
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Oral Treatment for Acute HAE Attacks Is Ready for Phase 3
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Continue to Be Constructive Ahead of 2019 Clinical Catalysts; Reit Buy and $13PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
We Find Zenith Results Satisfying; Reit Buy and $13 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
We Find Zenith Results Satisfying; Reit Buy and $13 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Gleaning Information From Proxy Statement; Reit Buy and Raising PT to $13
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Business as Usual as the HAE Pipeline Continues to Progress
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A